Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Christadoss

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1996
IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravisC Deng, E Goluszko, S Baron, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1998
The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravisB Balasa, C Deng, J Lee, et al.
Clinical Immunology and Immunopathology|July 1, 1998
The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravisV Dedhia, E Goluszko, B Wu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1981
Genetic control of experimental autoimmune myasthenia gravis in mice. II. Lymphocyte proliferative response to acetylcholine receptor is dependent on Lyt-1+23- cellsP Christadoss, C J Krco, V A Lennon, et al.
Annals of the New York Academy of Sciences|June 21, 1993
Molecular immunopathogenesis of myasthenia gravis using MHC class II mutant and transgenic miceM Shenoy, C David, M Oshima, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1982
Genetic control of experimental autoimmune myasthenia gravis in mice. III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptorsP Christadoss, V A Lennon, C J Krco, et al.
Neurology|December 30, 2004
Etanercept treatment in corticosteroid-dependent myasthenia gravisJ Rowin, M N Meriggioli, E Tüzün, et al.
Cellular Immunology|July 15, 1983
Deficient T-cell mitogen response in murine experimental autoimmune myasthenia gravis: a defect in the adherent cell populationP Christadoss, M Dauphinee, J Lindstrom, et al.
Journal of Neuroimmunology|November 7, 2000
Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChRM A Poussin, E Goluszko, T K Hughes, et al.
Journal of Autoimmunity|November 20, 2001
HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 productionM A Poussin, E Goluszko, C S David, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1996
IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravisC Deng, E Goluszko, S Baron, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1998
The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravisB Balasa, C Deng, J Lee, et al.
Clinical Immunology and Immunopathology|July 1, 1998
The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravisV Dedhia, E Goluszko, B Wu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1981
Genetic control of experimental autoimmune myasthenia gravis in mice. II. Lymphocyte proliferative response to acetylcholine receptor is dependent on Lyt-1+23- cellsP Christadoss, C J Krco, V A Lennon, et al.
Annals of the New York Academy of Sciences|June 21, 1993
Molecular immunopathogenesis of myasthenia gravis using MHC class II mutant and transgenic miceM Shenoy, C David, M Oshima, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1982
Genetic control of experimental autoimmune myasthenia gravis in mice. III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptorsP Christadoss, V A Lennon, C J Krco, et al.
Neurology|December 30, 2004
Etanercept treatment in corticosteroid-dependent myasthenia gravisJ Rowin, M N Meriggioli, E Tüzün, et al.
Cellular Immunology|July 15, 1983
Deficient T-cell mitogen response in murine experimental autoimmune myasthenia gravis: a defect in the adherent cell populationP Christadoss, M Dauphinee, J Lindstrom, et al.
Journal of Neuroimmunology|November 7, 2000
Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChRM A Poussin, E Goluszko, T K Hughes, et al.
Journal of Autoimmunity|November 20, 2001
HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 productionM A Poussin, E Goluszko, C S David, et al.
Pageof 5